Login / Register | 0 items - $ 0.00 CONTACT US

AlcoPro - Drug and Alcohol Testing Products & DOT Training

  • Products
  • Training
    • DOT Drug and Alcohol Training
    • Employer Substance Abuse Awareness Training
    • Hotels in Knoxville
    • Training Materials
    • DOT Regulations Knowledge Base
  • Knowledge Base
  • Repairs & Services
  • Resources
    • Catalogs
    • Knowledge Base
    • Buyer’s Guide
    • Product Document Library
    • Drug Test Finder
    • Drink Wheel
    • Window of Detection Tool
    • Breath Alcohol Instrument Mouthpiece Chart
  • News
    • News
    • AlcoPro Blog
    • Sign Up – AlcoPro Blog
  • Customer Service
    • Order & Return Policy
    • Shipping Information
    • Apply for Tax Exempt Status
    • Satisfaction & Warranty Policy
    • Repair Services and Technical Support
    • Privacy Policy
    • Customer Reviews
  • Contact Us
    • Contact Us
    • Quote Request
    • Catalog Request
    • Product Sample Request
    • BAC Wheel Request
    • Customer Reviews
  • About Us

800.227.9890

Follow Us on FacebookFollow Us on TwitterFollow Us on LinkedIn

Expanded Opioid Testing: Regulation Changes

January 24, 2017 by Jennie Lee-Pace Leave a Comment

Expanded Opioid Testing: Regulation Changes.

HHS Expanded Opioid Testing and Allowance of Oral Fluid Testing.

On Monday, January 23, 2017 the Department of Health and Human Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA) agencies issued a notice for revisions to the the mandatory guidelines for federal workplace drug trusting programs using urine as a testing method.

The Secretary of Health and Human Services with SAMSHA, allow federal executive branch agencies to test for additional Schedule II drugs of the Controlled Substances Act which includes oxycodone, oxymorphone, hydrocodone and hydromorphone in federal drug-free workplace programs. Additionally, the notice calls for the removal of methylenedioxyethylamphetamine (MDEA) from the authorized drugs in Section 3.4,  but adds methylenedioxyamphetamine (MDA) as an initial test analyte. The notice raises the lower pH cutoff from 3 to 4 for identifying specimens as adulterated, and requires MRO requalification training and re-examination at least every five years after the initial MRO certification. The revisions, which will take effect on October 1, 2017, will allow federal agencies to authorize collection of an alternate specimen (e.g., oral fluid) when a donor is unable to provide a sufficient amount of urine specimen at the collection site. Many of the wording changes and reorganization of the UrMG were made for clarity, to use current scientific terminology or preferred grammar, and for consistency with the OFMG.

Download and read the notice

DOT Proposed Regulation Changes to Allow Expanded Opioid Panel, Remove Blind Specimen Requirement for C/TPAs.

Also, on Monday, January 23, 2017, the Department of Transportation issued a proposed amendment to its drug-testing program regulation to allow for the addition of four opioids to its drug-testing panel. These additions include hydrocodone, hydromorphone, oxymorphone, and oxycodone. The proposal includes adding methylenedioxyamphetamine (MDA) as an initial test analyte and removes methylenedioxyethylamphetamine,(MDEA) as a confirmatory test analyte. The proposed revision of the drug-testing panel is intended to harmonize with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing. This proposal also adds clarification to certain drug-testing program provisions where necessary, removes outdated information in the regulations that is no longer needed, and proposes to remove the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The DOT asks for comments to the notice of proposed rule-making by March 24, 2017.

Download and Read the Notice

DATIA will be analyzing both notices, providing comments on the DOT proposed regulations, and providing members with clear and concise guidance on how these new regulations will impact their operations. Representatives from both DOT and HHS will be at the DATIA Annual Conference to discuss these new changes.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

ABOUT ALCOPRO

Since 1982, AlcoPro has supplied and manufactured the most accurate drug and alcohol testing instruments, kits, and supplies for professional use. We take pride in maintaining our industry-wide reputation for accuracy and quality as we help you—our top priority—perform alcohol and drug screenings and tests with greater precision and confidence.

Subscribe to Our Blog

  • This field is for validation purposes and should be left unchanged.

800.227.9890
Follow Us on FacebookFollow Us on TwitterFollow Us on LinkedInFollow Us on YouTube

Privacy Policy

© 2023 AlcoPro.
All Rights Reserved.

Custom Website Design & Development by VIEO Design